REGENERON PHARMACEUTICALS, INC. Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss
REGENERON PHARMACEUTICALS, INC. (REGN) had Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss of $2.00 million as of 2025-09-30, per its 10-Q filed 2025-10-28.
Financial Statements › Notes › Debt and Equity Securities › Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss
us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss · last filed 2025-10-28
- 2025-09-30: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss $2.00M.
- 2025-06-30: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss $2.90M.
- 2025-03-31: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss $6.30M.
- 2024-12-31: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss $21.00M.
| Period end | Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss | Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss as first filed |
|---|---|---|
| 2025-09-30 | $2.00M 10-Q · filed 2025-10-28 | |
| 2025-06-30 | $2.90M 10-Q · filed 2025-08-01 | |
| 2025-03-31 | $6.30M 10-Q · filed 2025-04-29 | |
| 2024-12-31 | $21.00M 10-Q · filed 2025-10-28 | |
| 2024-09-30 | $800.00K 10-Q · filed 2024-10-31 | |
| 2024-06-30 | $23.20M 10-Q · filed 2024-08-01 | |
| 2024-03-31 | $27.90M 10-Q · filed 2024-05-02 | |
| 2023-12-31 | $9.00M 10-K · filed 2025-02-05 | |
| 2023-09-30 | $52.20M 10-Q · filed 2023-11-02 | |
| 2023-06-30 | $37.10M 10-Q · filed 2023-08-03 | |
| 2023-03-31 | $8.40M 10-Q · filed 2023-05-04 | |
| 2022-12-31 | $76.90M 10-K · filed 2024-02-05 | |
| 2022-09-30 | $233.40M 10-Q · filed 2022-11-03 | |
| 2022-06-30 | $263.10M 10-Q · filed 2022-08-03 | |
| 2022-03-31 | $202.90M 10-Q · filed 2022-05-04 | |
| 2021-12-31 | $42.30M 10-K · filed 2023-02-06 | |
| 2021-09-30 | $7.00M 10-Q · filed 2021-11-04 | |
| 2021-06-30 | $3.70M 10-Q · filed 2021-08-05 | |
| 2021-03-31 | $6.20M 10-Q · filed 2021-05-06 | |
| 2020-09-30 | $800.00K 10-Q · filed 2020-11-05 | |
| 2020-03-31 | $31.90M 10-Q · filed 2020-05-05 | |
| 2019-12-31 | $300.00K 10-Q · filed 2020-11-05 | |
| 2019-09-30 | $400.00K 10-Q · filed 2019-11-05 | |
| 2019-06-30 | $200.00K 10-Q · filed 2019-08-06 | |
| 2019-03-31 | $300.00K 10-Q · filed 2019-05-07 | |
| 2018-12-31 | $6.10M 10-K · filed 2020-02-07 | |
| 2018-09-30 | $11.15M 10-Q · filed 2018-11-06 | |
| 2018-06-30 | $15.72M 10-Q · filed 2018-08-02 | |
| 2017-12-31 | $5.30M 10-K · filed 2019-02-07 | $5.34M 10-Q · filed 2018-08-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 |